TH Stock Overview A biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Theratechnologies Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Theratechnologies Historical stock prices Current Share Price CA$2.50 52 Week High CA$3.43 52 Week Low CA$1.59 Beta 1.75 1 Month Change 47.06% 3 Month Change 47.06% 1 Year Change 19.05% 3 Year Change -84.18% 5 Year Change -83.93% Change since IPO -88.89%
Recent News & Updates
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Dec 11
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1B, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer Dec 10 Theratechnologies Inc. Announces Resume Production of EGRIFTA SV Dec 04
Forecast breakeven date pushed back to 2025 Nov 30
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review Nov 26
Theratechnologies Presents Data on Tesamorelin's Role in Reducing Cardiovascular Risk in People with Hiv At Idweek 2024 Oct 18 See more updates
Theratechnologies Inc. Receives March 2025 PDUFA Goal Date for Updated Tesamorelin F8 Formulation sBLA Dec 11
Theratechnologies Announces Preliminary Tolerability and Efficacy Data from Phase 1B, Dose-Ranging Trial of Sudocetaxel Zendusortide in Patients with Advanced Ovarian Cancer Dec 10 Theratechnologies Inc. Announces Resume Production of EGRIFTA SV Dec 04
Forecast breakeven date pushed back to 2025 Nov 30
Theratechnologies Submits Updated Tesamorelin F8 Formulation sBLA for FDA Review Nov 26
Theratechnologies Presents Data on Tesamorelin's Role in Reducing Cardiovascular Risk in People with Hiv At Idweek 2024 Oct 18 Theratechnologies Inc. Revises Earnings Guidance for the Fiscal Year 2024 Oct 11
Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Oct 10
Forecast breakeven date pushed back to 2025 Sep 18
Second quarter 2024 earnings: EPS and revenues exceed analyst expectations Jul 11
Theratechnologies Inc. Provides Earnings Guidance for the Year 2024 Jul 10
Insufficient new directors Jul 01
Theratechnologies Inc. to Report Q2, 2024 Results on Jul 10, 2024 Jun 27
Forecast to breakeven in 2024 Jun 02
Consensus EPS estimates upgraded to US$0.085 loss May 21
Theratechnologies Inc. Announces Frank Holler as Chair of the Board of Directors May 11
Increases to CEO Compensation Might Be Put On Hold For Now at Theratechnologies Inc. (TSE:TH) May 03
Consensus estimates of losses per share improve by 70% Apr 17
First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Apr 11
Theratechnologies Inc. Provides Earnings Guidance for the Fiscal Year 2024 Apr 10
Theratechnologies Inc.'s (TSE:TH) Share Price Boosted 25% But Its Business Prospects Need A Lift Too Apr 10
Theratechnologies Inc. Preclinical Data Presentation At AACR 2024 Highlights Versatility and Flexibility of SORT1+ Technology™ Oncology Platform Apr 10
Theratechnologies Inc. Appoints Elina Tea to its Board of Directors and as Member of the Company's Audit Committee Apr 06
Theratechnologies Inc. to Report Q1, 2024 Results on Apr 10, 2024 Apr 04 Theratechnologies Inc. Initiates Increased Dose Level in Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
Theratechnologies Inc., Annual General Meeting, May 09, 2024 Mar 09 Theratechnologies Inc. Announces Board Changes
Consensus EPS estimates fall by 12% Feb 28
Earnings Update: Theratechnologies Inc. (TSE:TH) Just Reported And Analysts Are Trimming Their Forecasts Feb 24
Price target increased by 300% to CA$8.00 Feb 23
Full year 2023 earnings: EPS and revenues miss analyst expectations Feb 22 Theratechnologies Inc. Provides Earnings Guidance for the Year 2024
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer Feb 16
Investors Don't See Light At End Of Theratechnologies Inc.'s (TSE:TH) Tunnel And Push Stock Down 27% Feb 07
Theratechnologies Inc. to Report Q4, 2023 Results on Feb 21, 2024 Feb 07 Theratechnologies Inc. Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
Theratechnologies Inc. Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose Dec 13 Soleus Capital Management Engages in Discussions with Theratechnologies Nov 29
Theratechnologies Inc. announced that it has received $12.5 million in funding from Investissement Québec Nov 01
Theratechnologies Inc. has completed a Follow-on Equity Offering in the amount of $12.5 million. Oct 28
New major risk - Shareholder dilution Oct 27 Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec Theratechnologies Inc. announced that it expects to receive $12.5 million in funding from Investissement Québec Oct 26
Theratechnologies Inc. Ibalizumab Demonstrates Cost-Effectiveness as an Addition to Routine Clinical Care in Heavily Treatment-Experienced People with HIV Oct 20 Theratechnologies Inc. Presents Data at ID Week Showing Tesamorelin Reduces Visceral Adipose Tissue (VAT) and Liver Fat in People with HIV on Integrase Inhibitors (INSTIs)
Theratechnologies Announces Dosing of First Patient in Updated Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer Oct 13
Theratechnologies Inc. Receives January 2024 PDUFA Goal Date for Tesamorelin F8 Formulation sBLA Oct 06
Third quarter 2023 earnings: EPS exceeds analyst expectations Sep 27
Theratechnologies Submits Tesamorelin F8 Formulation Sbla for Fda Review Sep 26
Theratechnologies Inc. to Report Q3, 2023 Results on Sep 26, 2023 Sep 19
Theratechnologies Inc. Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide Aug 31
New minor risk - Share price stability Aug 20 Theratechnologies Completes 1-For-4 Reverse Stock Split to Regain Compliance with Nasdaq Listing Requirements Aug 01
Theratechnologies Inc. Announces Resignation of Gary Littlejohn as Board of Directors and Member of Its Audit Committee
Consensus EPS estimates fall by 37% Jul 19
No longer forecast to breakeven Jul 14
Theratechnologies Inc. Revises Revenue Guidance for the Fiscal Year of 2023 Jul 13
New major risk - Revenue and earnings growth Jul 13
Second quarter 2023 earnings: EPS and revenues miss analyst expectations Jul 13
New minor risk - Profitability Jul 05
Forecast to breakeven in 2025 Jul 04
Theratechnologies Inc. to Report Q2, 2023 Results on Jul 12, 2023 Jun 30 Shareholder Returns TH CA Biotechs CA Market 7D 16.3% -1.8% -3.7% 1Y 19.0% 15.3% 15.0%
See full shareholder returns
Return vs Market: TH exceeded the Canadian Market which returned 15% over the past year.
Price Volatility Is TH's price volatile compared to industry and market? TH volatility TH Average Weekly Movement 7.5% Biotechs Industry Average Movement 12.9% Market Average Movement 8.2% 10% most volatile stocks in CA Market 17.6% 10% least volatile stocks in CA Market 2.9%
Stable Share Price: TH has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: TH's weekly volatility (8%) has been stable over the past year.
About the Company Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers.
Show more Theratechnologies Inc. Fundamentals Summary How do Theratechnologies's earnings and revenue compare to its market cap? TH fundamental statistics Market cap CA$110.35m Earnings (TTM ) -CA$4.53m Revenue (TTM ) CA$121.02m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) TH income statement (TTM ) Revenue US$84.32m Cost of Revenue US$19.42m Gross Profit US$64.90m Other Expenses US$68.06m Earnings -US$3.16m
Last Reported Earnings
Aug 31, 2024
Earnings per share (EPS) -0.069 Gross Margin 76.97% Net Profit Margin -3.75% Debt/Equity Ratio -290.4%
How did TH perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/20 23:19 End of Day Share Price 2024/12/20 00:00 Earnings 2024/08/31 Annual Earnings 2023/11/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Theratechnologies Inc. is covered by 18 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jason Zhang BMO Capital Markets U.S. (Historical) Douglas Loe Byron Capital Markets Dewey Steadman Canaccord Genuity
Show 15 more analysts 
